Related references
Note: Only part of the references are listed.Wrist-worn accelerometers: recommending ∼1.0 mg as the minimum clinically important difference (MCID) in daily average acceleration for inactive adults
Alex Rowlands et al.
BRITISH JOURNAL OF SPORTS MEDICINE (2021)
Mechanisms of weight regain.
Luca Busetto et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial
Yvo J. M. Op den Kamp et al.
DIABETES CARE (2021)
Improvements in Glycemic Control After Acute Moderate-Intensity Continuous or High-Intensity Interval Exercise Are Greater in South Asians Than White Europeans With Nondiabetic Hyperglycemia: A Randomized Crossover Study
Jack A. Sargeant et al.
DIABETES CARE (2021)
Combined effect of canagliflozin and exercise training on high-fat diet-fed mice
Kenichi Tanaka et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2020)
Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study
Ikuro Matsuba et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Metabolic Effects of Breaking Prolonged Sitting With Standing or Light Walking in Older South Asians and White Europeans: A Randomized Acute Study
Thomas Yates et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2020)
The drive to eat in homo sapiens: Energy expenditure drives energy intake
John E. Blundell et al.
PHYSIOLOGY & BEHAVIOR (2020)
Revisiting the Compensatory Theory as an explanatory model for relapse in obesity management
Catia Martins et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2020)
Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Andre J. Scheen
NATURE REVIEWS ENDOCRINOLOGY (2020)
Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study)
Hiroshi Miura et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
Emily Brown et al.
OBESITY REVIEWS (2019)
Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes
Peili Wu et al.
HORMONE AND METABOLIC RESEARCH (2019)
Does Dapagliflozin Affect Energy Intake and Appetite? A Randomized, Controlled Exploratory Study in Healthy Subjects
Elizabeth Bertran et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes-The Energize Study
Surya Panicker Rajeev et al.
DIABETES (2018)
Incretin hormones: Their role in health and disease
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2018)
Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
Hiroaki Ueno et al.
DIABETES THERAPY (2018)
Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
Hiroaki Ueno et al.
DIABETES THERAPY (2018)
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol
Surya Panicker Rajeev et al.
BMJ OPEN (2017)
Effects of ghrelin in energy balance and body weight homeostasis
Laura Mihalache et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2016)
How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake
David Polidori et al.
Obesity (2016)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2013)
Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
James J. Devenny et al.
OBESITY (2012)
Biology's response to dieting: the impetus for weight regain
Paul S. MacLean et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2011)
Long-Term Persistence of Hormonal Adaptations to Weight Loss
Priya Sumithran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Influence of resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin, and peptide YY in healthy males
David R. Broom et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2009)
Subject Standardization, Acclimatization, and Sample Processing Affect Gut Hormone Levels and Appetite in Humans
Keval Chandarana et al.
GASTROENTEROLOGY (2009)
Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions
GH Ballantyne
OBESITY SURGERY (2006)
Attenuated peptide YY release in obese subjects is associated with reduced satiety
CW le Roux et al.
ENDOCRINOLOGY (2006)
Effects of a fixed meal pattern on ghrelin secretion: Evidence for a learned response independent of nutrient status
DL Drazen et al.
ENDOCRINOLOGY (2006)
The function of leptin in nutrition; Weight, and physiology
JM Friedman
NUTRITION REVIEWS (2002)
A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans
C Verdich et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Reproducibility, power and validity of visual analogue scares in assessment of appetite sensations in single test meal studies
A Flint et al.
INTERNATIONAL JOURNAL OF OBESITY (2000)
Share Paper
